Autolus Therapeutics (NASDAQ: AUTL) reported Q1 EPS of ($0.24), $0.16 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $10.09 million versus the consensus estimate of $33.4 million.

For earnings history and earnings-related data on Autolus Therapeutics (AUTL) click here.